Evaluation of the anti-proliferative activity of three new pyrazole compounds in sensitive and resistant tumor cell lines

Pharmacological Reports

Volumn 65, Issue 3, 2013, Pages 717-723

  Viale, Maurizio ^a   Anzaldi, Maria ^b   Aiello, Cinzia ^a   Fenoglio, Carla ^c   Albicini, Federica ^c   Emionite, Laura ^a   Gangemi, Rosaria ^a   Balbi, Alessandro ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

Anti proliferative activity; Drug resistance mechanisms; Pyrazole compounds

Indexed keywords

2 [1 (4 CHLOROPHENYL) 1H PYRAZOL 5 YL] 5 METHOXYPHENOL; 2 [5 (4 METHOXYPHENYL) 1H PYRAZOL 1 YL]PYRIDINE; 5 METHOXY 2 [1 (PYRIDIN 2 YL) 1H PYRAZOL 5 YL]PHENOL; ANTIMITOTIC AGENT; FLUOROURACIL; MULTIDRUG RESISTANCE PROTEIN 1; UNCLASSIFIED DRUG; VINCRISTINE;

ANIMAL CELL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DEPOLYMERIZATION; DRUG MECHANISM; DRUG SENSITIVITY; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MICROTUBULE; MITOSIS INHIBITION; NONHUMAN; TUMOR CELL LINE;

ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HEK293 CELLS; HUMANS; MCF-7 CELLS; MEMBRANE TRANSPORT PROTEINS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; P-GLYCOPROTEIN; PYRAZOLES; TUMOR CELLS, CULTURED;

EID: 84884483142     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(13)71050-8     Document Type: Article

References (28)

1. Abadi AH, Eissa AA, Hassan GS: Synthesis of novel 1,3,4-trisubstituted pyrazole derivatives and their evaluation as antitumor and antiangiogenic agents. Chem Pharm Bull, 2003, 51, 838-844. (Pubitemid 41694788)
2. Alaoui Jamali MA, Yin MB, Mazzoni A, Bankusli I, Rustum YM: Relationship between cytotoxicity, drug accumulation, DNA damage and repair of human ovarian cancer cells treated with doxorubicin, modulation by the tiapamil analog RO11-2933. Cancer Chemother Pharmacol, 1989, 25, 77-83. (Pubitemid 20009431)
3. Anzaldi M, Sottofattori E, Rizzetto R, Granello Di Casaleto B, Balbi A: Synthesis and antimicrobial activity of heterocyclic ionone-like derivatives. Eur J Med Chem, 1999, 34, 837-842. (Pubitemid 29533851)
4. Anzaldi M, Macciò C, Mazzei M, Bertolotto M, Ottonello L, Dallegri F, Balbi A: Antiproliferative and proapoptotic activities of a new class of pyrazole derivatives in HL-60 cells. Chem Biodivers, 2009, 6, 1674-1687.
5. Aschele C, Sobrero A, Faderan MA, Bertino JR: Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res, 1992, 52, 1855-1864.
6. Balbi A, Anzaldi M, Macciò C, Aiello C, Mazzei M, Gangemi R, Castagnola P et al.: Synthesis and biological evaluation of novel pyrazole derivatives with anticancer activity. Eur J Med Chem, 2011, 46, 5293-5309.
7. Balbi A, Anzaldi M, Mazzei M, Miele M, Bertolotto M, Ottonello L, Dallegri F: Synthesis and biological evaluation of novel heterocyclic ionone-like derivatives as anti-inflammatory agents. Bioorg Med Chem, 2006, 14, 5152-5160. (Pubitemid 43903267)
8. Barbieri F, Alama A, Tasso B, Boido V, Bruzzo C, Sparatore F: Quinolizidinyl derivatives of iminodibenzyl and phenotiazine as multidrug resistance modulators in ovarian cancer cells. Invest New Drug, 2003, 21, 413-420. (Pubitemid 38124980)
9. Cafaggi S, Russo E, Stefani R, Leardi R, Caviglioli G, Parodi B, Bignardi G et al.: Preparation and evaluation of nanoparticles made of chitosan or N-trimethyl chitosan and a cisplatin-alginate complex. J Control Release, 2007, 121, 110-123. (Pubitemid 47161043)
10. Cho N, Kamaura M, Yogo T, Imoto H: Preparation of pyrazole derivatives as improvement of insulin resistance. PCT Int Appl 2009, WO 2009139340.
11. Doyle LA, Ross D, Ordonez JY, Yang W: An etoposideresistant small cell lung cancer subline overexpresses the multidrug resistance associated protein (MRP) gene. Br J Cancer, 1995, 72, 535-542.
12. Dugi K, Mark M, Himmelsbach F: Pharmaceutical composition comprising a pyrazole-O-glucoside derivative for treating diabetes. PCT Int Appl 2009, WO 2009022009.
13. Elguero J, Goya P, Jagerovic N, Silva AMS: Pyrazoles as drugs: facts and fantasies. In: Targets in Heterocyclic Systems: Eds. Attanasi OA, Spinelli D, Royal Society of Chemistry, Cambridge, 2002, 52-98.
14. Gatti L, Zunino F: Overview of tumor cell chemoresistance mechanisms. Methods Mol Med, 2005, 111, 127-148.
15. Hussain RF, Nouri AME, Oliver RTD: A new approach for measurement of cytotoxicity using colorimetric assay. J Immunol Methods, 1993, 160, 89-96.
16. Insuasty B, Tigreros A, Orozco F, Quiroga J, Abonia R, Nogueras M, Sanchez A, Cobo J: Synthesis of novel pyrazolic analogues of chalcones and their 3-aryl-4-(3-aryl-4,5-dihydro-1H-pyrazol-5-yl)-1-phenyl-1H-pyrazole derivatives as potential antitumor agents. Bioorg Med Chem, 2010, 18, 4965-4974.
17. Kavallaris M, Burkhart CA, Horwits SB: Antisense oligonucleotides to class III β-tubulin sensitize drug-resistant cells to taxol. Br J Cancer, 1999, 80, 1020-1025. (Pubitemid 29233923)
18. Kavallaris M, Kuo DYS, Burkhart CA, Regi DL, Norris MD, Haber M, Horwitz SB: Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific β-tubulin isotypes. J Clin Invest, 1997, 100, 1282-1293. (Pubitemid 27386315)
19. Labbozzetta M, Baruchello R, Marchetti P, Gueli MC, Poma P, Notarbartolo M, Simoni D, D'Alessandro N: Lack of nucleophilic addition in the isoxazole and pyrazole diketone modified analogs of curcumin, implications for their antitumor and chemosensitizing activities. Chem-Biol Interact, 2009, 181, 29-36.
20. Ludwig S, Planz O, Sedlacek HH, Pleschka S: Use of caspase inhibitors as antiviral agents, and test system for their discovery. PCT Int Appl 2004, WO 2004085682 A2 20041007.
21. Momose Y, Maekawa T, Odaka H, Kimura H: Preparation of pyrazolyl-and pyrrolylalkanoic acid derivatives with hypoglycemic and hypolipidemic activity. PCT Int Appl 2001, WO 2001038325.
22. Perchellet EM, Ward MM, Skaltsounis AL, Kostakis IK, Pouli N, Marakos P, Perchellet JP: Antiproliferative and proapoptotic activities of pyranoxanthenones, pyranothioxanthenones and their pyrazole-fused derivatives in HL-60 cells. Anticancer Res, 2006, 26, 2791-2804. (Pubitemid 44161766)
23. Pevarello P, Brasca MG, Amici R, Orsini P, Traquandi G, Corti L, Piutti C et al.: 3-Aminopyrazole inhibitors of CDK2/Cyclin A as antitumor agents. 1. Lead Finding. J Med Chem, 2004, 47, 3367-3380. (Pubitemid 38746088)
24. Richon VM, Schulte N, Eastman A: Multiple mechanisms of resistance to cis-diamminedichloroplatinum(II) in murine leukemia L1210 cells. Cancer Res, 1987, 47, 2056-2061. (Pubitemid 17074608)
25. Robey RW, Honjo Y, Morisaki K, Nadjem TA, Runge S, Risbood M, Poruchynsky MS, Bates SE: Mutations at amino acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br J Cancer, 2003, 89, 1971-1978. (Pubitemid 37533279)
26. Szabo G, Fischer J, Kis-Varga A, Gyires K: New celecoxib derivatives as anti-inflammatory agents. J Med Chem, 2008, 51, 142-147.
27. Tanitame A, Oyamada Y, Ofuji K, Fujimoto M, Suzuki K, Ueda T, Terauchi H et al.: Synthesis and antibacterial activity of novel and potent DNA gyrase inhibitors with azole ring. Bioorg Med Chem, 2004, 12, 5515-5524. (Pubitemid 39304051)
28. Tanitame A, Oyamada Y, Ofuji K, Terauchi H, Kawasaki M, Wachi M, Yamagishi J: Synthesis and antibacterial activity of a novel series of DNA gyrase inhibitors: 5-[(E)-2-arylvinyl]pyrazoles. Bioorg Med Chem Lett, 2005, 15, 4299-4303. (Pubitemid 41188007)